Abstract：Objective To study the effect of Raloxifene on negative symptoms, cognitive function, and quality of life in menopausal patients with chronic schizophrenia. Methods A total of 80 postmenopausal female schizophrenics with negative symptoms and long-term treatment with Clozapine from the outpatient department of Wuhu Fourth People’s Hospital, Anhui Province from January 2021 to January 2022 were selected as the research object. According to random number table method, they were divided into control group (40 cases) and study group (40 cases). The control group was treated with Clozapine, and the research group was treated with Clozapine and Raloxifene, the treatment lasted for 12 weeks. The positive and negative symptom scale (PANSS) score, scale for assessment of negative symptoms (SANS) score, serum estradiol (E2) levels, the repeatable battery for the assessment of neuropsychological status (RBANS) score, and generic quality of life inventory-74 (GQOLI-74) score were compared between two groups before and after treatment; the occurrence of adverse reactions during treatment was observed. Results After treatment, the SANS score and PANSS score of two groups were lower than those before treatment, and those in study group were higher than those in control group (P＜0.05), and the E2 level of two groups was higher than that before treatment, and that in study group was higher than that in control group (P＜0.05). After treatment, the scores of immediate memory, attention, verbal function, delayed memory, and visual span in two groups were higher than those before treatment, and those in study group were higher than those in control group (P＜0.05). After treatment, the scores of material life status, social function, physical function, and psychological function of two groups were higher than those before treatment, and those in study group were higher than those in control group (P＜0.05). There was no significant difference in the total incidence of adverse reactions between two groups (P＞0.05). Conclusion Raloxifene can effectively relieve the negative symptoms of menopausal patients with chronic schizophrenia, improve the quality of life and cognitive function of patients, and has high safety.
朱明 张恩 徐滢. 雷洛昔芬对绝经期慢性精神分裂症患者的阴性症状及认知功能和生活质量的影响[J]. 中国医药导报, 2023, 20(29): 95-98.
ZHU Ming ZHANG En XU Ying. Effect of Raloxifene on negative symptoms, cognitive function, and quality of life in menopausal patients with chronic schizophrenia. 中国医药导报, 2023, 20(29): 95-98.
[1] Guillin O. Schizophrenia：10 key messages [J]. Rev Prat，2021，71（1）：64. [2] 司天梅，于欣.难治性精神分裂症的研究进展[J].中华精神科杂志，2018，51（3）：157-162. [3] Wang Q，Dong X，Wang Y，et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia：a meta-analysis of randomized controlled trials [J]. Arch Womens Ment Health，2018，21（1）：31-41. [4] 董景五.推广应用“国际疾病分类第十次修订本（ICD-10）”的几点体会[J].中国临床康复，2002，6（20）：3038-3039. [5] 金金，何燕玲，周亮，等.精神病症状维度评定量表中文版的效度和信度[J].中国心理卫生杂志，2020，34（11）：932-939. [6] 姚晶，崔界峰，陈楠，等.简明阴性症状量表中文版的效度、信度检验[J].中国心理卫生杂志，2014，28（4）：302- 307. [7] 张保华，谭云龙，张五芳，等.重复性成套神经心理状态测验的信度、效度分析[J].中国心理卫生杂志，2008，22（12）：865-869. [8] 张作记.生活质量评定量表选介[J].中国行为医学科学，2001，10（5）：455. [9] 陈春棉，姜德国，陈策，等.格拉斯哥抗精神病药副反应评定量表中文版信效度分析[J].中华行为医学与脑科学杂志，2020，29（1）：79-83. [10] 李国华，孟琳琳，黄薇，等.慢性精神分裂症患者神经认知功能与共情能力的相关性研究[J].现代预防医学，2022，49（24）：4495-4499. [11] Richetto J，Meyer U. Epigenetic Modifications in Schizophrenia and Related Disorders：Molecular Scars of Environmental Exposures and Source of Phenotypic Variability [J]. Biol Psychiatry，2021，89（3）：215-226. [12] 田文豪，程哲，陈雷音，等.缺陷型精神分裂症发病机制、诊断与治疗的研究进展[J].神经疾病与精神卫生，2022，22（6）：414-419. [13] Ma HY，Chen S，Lu LL，et al. Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease：A Systematic Review and Meta-Analysis [J]. Horm Metab Res，2021，53（11）：730-737. [14] 廖盛楠，吕炜桐，唐权，等.选择性雌激素受体调节剂抑制变异链球菌的作用探究[J].华西口腔医学杂志，2022， 40（2）：218-224. [15] 郭宗儒.以雌受体为靶标的骨质疏松治疗药雷洛昔芬[J].药学学报，2021，56（7）：2033-2038. [16] 陈晶晶，蔡俊男，李晓一，等.雷洛昔芬联合阿立哌唑治疗绝经期女性精神分裂症患者效果观察[J].浙江医学，2021，43（9）：971-975. [17] 孙秋芳，施永斌，褚庆文，等.雌激素对绝经后女性精神分裂症患者认知功能的影响[J].国际精神病学杂志，2020，47（5）：913-916. [18] Brand BA，de Boer JN，Sommer IEC. Estrogens in schizop- hrenia：progress，current challenges and opportunities [J]. Curr Opin Psychiatry，2021，34（3）：228-237. [19] 吕钦谕，易正辉.精神分裂症雌激素功能不足假说与选择性雌激素受体调节剂研究进展[J].中华精神科杂志，2018，51（6）：385-388. [20] 于健瑾，宋佳起，赵青，等.首发精神分裂症性激素与精神症状及认知功能关联性研究[J].中国神经精神疾病杂志，2020，46（8）：460-465. [21] Veenman L. Raloxifene as Treatment for Various Types of Brain Injuries and Neurodegenerative Diseases：A Good Start [J]. Int J Mol Sci，2020，21（20）：7586. [22] de Boer J，Prikken M，Lei WU，et al. The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder：a systematic review and meta-analysis [J]. NPJ Schizophr，2018，4（1）：1. [23] 张晓芬，李林，黄雪竹，等.雷洛昔芬辅助治疗女性精神分裂症有效性和安全性Meta分析[J].中国药业，2020， 29（9）：144-147. [24] Vahdani B，Armani Kian A，Esmaeilzadeh A，et al. Adjunctive Raloxifene and Isradipine Improve Cognitive Functioning in Patients With Schizophrenia：A Pilot Study [J]. J Clin Psychopharmacol，2020，40（5）：457-463. [25] Huerta-Ramos E，Labad J，Cobo J，et al. Effects of raloxifene on cognition in postmenopausal women with schizo- phrenia：a 24-week double-blind，randomized，parallel，pla- cebo-controlled trial [J]. Eur Arch Psychiatry Clin Neurosci，2020，270（6）：729-737.
2023, Vol. 20 
京公网安备 11010502046598号